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ABSTRACT 
 
One and the same protein can self-assemble into amyloid fibrils with different 
morphologies. The phenomenon of fibril polymorphism is relevant biologically, 
because different fibril polymorphs can have different toxicity, but a predictive tool 
for which polymorph forms and under what conditions is absent. Here we consider 
the nucleation of polymorphic amyloid fibrils occurring by direct polymerization of 
monomeric proteins into fibrils and treat it within the framework of our newly 
developed non-standard nucleation theory, which allows the prediction of the 
concentration dependence of the nucleation rate for different fibril polymorphs. The 
results obtained highlight that the concentration dependence of the nucleation rate is 
closely linked with the protein solubility and a threshold monomer concentration 
below which fibril formation becomes biologically irrelevant. The presented relation 
between the nucleation rate, the fibril solubility, the threshold concentration and the 
binding energies of the fibril building blocks within fibrils might prove a valuable tool 
to design new experiments to control the formation of particular fibril polymorphs.  
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INTRODUCTION 
 
The structure and mechanism of formation of amyloid fibrils is being widely 
researched, not only because they are involved in many human diseases (1), but also 
due to the variety of applications as novel biomaterials in nanoscience (2). Although 
amyloid fibrils share a common cross-β-structure formed by intertwined layers of β-
sheets extending in direction parallel to the fibril axis (3), the conformation and the 
stacking of the β-strands in β-sheets can differ in fibrils of the same protein, a 
phenomenon known as fibril polymorphism (4-6). For example stacking 
polymorphism of fibrils has been observed in microcrystals of short hexapeptides 
where β-strands within β-sheets can arrange parallel or anti-parallel, and the 
orientation and stacking of β-sheets can differ (7). The stacking of β-sheets in fibrils 
can also lead to differences in the fibril thickness which in turn can lead to differences 
in their twisting behaviour and helical pitch as has been shown for fragments of 
Bovine serum albumin (8) and the TTR peptide (9). A well known example for 
conformational polymorphism are fibrils of the amyloid β (Aβ) peptide associated 
with Alzheimer’s disease that have several distinct morphologies including the ones 
where the β-strand in the fibril adopt an extended or a hairpin conformation (10, 11). 
The Aβ fibrils also exhibit packing polymorphism where the molecules are in the 
same conformation but pack in the fibril with different stacking or symmetry (11-13). 
Fibrils of numerous other proteins also show polymorphism including α-synuclei 
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(14), yeast and mammalian prion proteins (15, 16), and insulin (17) (see Refs.  (4-6, 
18) for a more complete list). The biological relevance of amyloid fibril 
polymorphism comes from the observation that the toxicity of polymorphs can differ 
(see e.g. Refs. (11, 19)). A prominent example is strain polymorphism and species 
barriers in prions. In this phenomenon, the prion protein can propagate multiple 
strains (fibril structures) each of which results in a different pathology. Propagation is 
sequence dependent, which prevents prion transmission between related species (see 
e.g. Refs. (15, 20, 21)). The conditions under which fibril polymorphism can be 
observed are manifold. The fibril morphology depends on intrinsic factors such as the 
protein amino acid sequence, and it has been observed that a single point mutation can 
switch the fibril morphology from predominately parallel to predominately 
antiparallel (22). It also depends on solution conditions (pH value (23), salts (24)) and 
other external factors (temperature (25), quiescent or agitated (11), seeds (26)), but 
even under the same conditions variations in the fibril morphology exist (27).   
The mechanism of how polymorphic amyloid fibrils form and under which 
conditions is subject of intense research (4-6). It is generally accepted that amyloid 
fibrils form by a nucleation and growth mechanism (e.g. Refs. (28-30)). The 
nucleation of amyloid fibrils refers to the process of random generation of nanofibrils 
that have the ability to grow irreversibly. Unless the nanofibril size exceeds the size of 
the nucleus, the nanofibril is more likely to dissolve than to grow. Depending on the 
solution conditions amyloid fibrils nucleate in one step (directly from the solution) or 
in two steps (step one being the appearance of nonfibrillar oligomers in the solution 
and step two being the oligomer conversion into fibrils) (31). In analogy to crystal 
nucleation where the structure of the nucleus determines the structure of the bulk 
solid, the structure of the fibril nucleus might determine the structure of the fibril 
formed in the solution. This implies that every fibril polymorph requires a distinct 
nucleation event and certain nucleation events may occur more frequently than others. 
Amyloid fibril growth refers to the process of addition of monomers to either the 
fibril ends or fibril surfaces leading to fibril lengthening and thickening, respectively. 
During growth the fibrils can be affected by other processes such as fibril 
fragmentation (11, 28), fibril coalescence, Ostwald ripening and secondary nucleation 
events such as the nucleation of fibrils on the surface of existing ones (32). Although 
a common feature of fibril polymorphism is that they are self-propagating, such 
growth effects can also lead to the formation of fibril polymorphs or determine which 
polymorph dominates. For example, fibril coalescence and Ostwald ripening can lead 
to fibrils with different thickness, and thus different twisting behaviour and helical 
pitch, as in the case of Bovine serum albumin (8) and the TTR peptide (9) mentioned 
above. It has also been shown that the fragmentation rate is the reason that Aβ40 fibril 
with two-fold symmetry form in agitated solutions and Aβ40 fibrils with three-fold 
symmetry form in absence of shear (11). 
In order to better understand why and how polymorphic amyloid fibrils form 
and under which conditions, it is necessary to develop a theoretical model of their 
formation. Models based on the protein physicochemical properties have been 
developed to predict the aggregation propensities but they are unable to differentiate 
between polymorphic fibril structures (33-36). Similarly, models on the molecular 
level based on rate equations have been used to analyse protein fibrillation 
experiments (28, 37, 38), but they are also unable to differentiate between 
polymorphic fibril structures because they work with a fixed fibril shape. Various 
Molecular Dynamic (MD) simulation studies using a full atomistic description of 
proteins have been reported that investigate fibril polymorphism (39-43), but at 
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present they are restricted to calculations of the thermodynamic stability of fibrils 
composed of short peptide fragments. Using a simplified protein model it has been 
possible to perform MD simulations, which show that one protein can self-assemble 
into different fibril morphologies, and that their formation can be kinetically (rather 
than thermodynamically) controlled (44).  
Here we approach the problem by considering the nucleation of amyloid 
fibrils into polymorphic structures when the process occurs in one step by a direct 
polymerization of monomers into fibrils. Two-step nucleation of polymorphic fibrils, 
and fibril polymorphism that occurs during fibril growth, or is determined by fibril 
growth, are not considered. Recently, our simulations have shown that amyloid fibril 
nucleation occurring by a direct polymerization of monomers is a peculiar kind of 
nucleation not complying with standard nucleation theory (45, 46), because the 
concept of the existence of a critical nucleus breaks down (the nucleus size does not 
have a unique value) and there exist jumps in the nucleation rate of many orders of 
magnitude at certain concentrations (47, 48). This called for the development of a new 
description of amyloid fibril nucleation which is able to describe this non-standard 
nucleation of amyloid fibrils (30, 49). The objective of this article is to apply this new 
nucleation model to the phenomenon of amyloid fibril polymorphism, and to predict 
how the fibril solubility, the threshold concentration below which fibril formation 
becomes biologically irrelevant, and the nucleation rate is affected by changes in the 
conformation and the stacking of the fibril building blocks (the β-strands) or their 
arrangement within the fibril. Our considerations of fibril polymorphism pertain to 
changes in (i) the β-strand length associated with the onset of polyglutamine disorders 
(50), (ii) the conformation of the β-strand from extended to a hairpin reported for 
Aβ40 (10), (iii) the parallel and anti-parallel stacking of β-strands in β-sheets as 
observed in short peptides and natural proteins (7, 22), (iv) and the asymmetry in the 
hydrophobicity between the two β-sheet surfaces that can lead to different stacking of 
β-sheets in fibrils (7). The emphasis of this work is to reveal general rules that 
underlie the nucleation of one and the same protein into different fibril polymorphs, to 
provide conceptual insight into factors that can tip the nucleation process in favour of 
one or another fibril polymorph. For this reason we will apply our theoretical 
framework to a model peptide rather than to a specific protein.   
 
MATERIALS AND METHODS 
 
Model  
In our model (30, 49, 51), each β-strand (a segment of a protein chain composed of 
typically up to ten amino acids) is represented by a right rectangular prism (Figure 1). 
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Figure 1. Phase diagram for fibrils composed of β-strands with one WH (blue) and a 
SH (red) side. The fibril solubility  indicates the concentration ranges in which the 
protein solution is in stable ( ) or metastable ( ) thermodynamic 
equilibrium at a given temperature. (a) In the metanucleation range ( ) the nucleus 
is a single β-strand. In the first ( ) nucleation range a 2β-sheet with two WH 
surfaces can elongate and the nucleus is a 1β-sheet with one β-strand attached with its 
SH side to the SH 1β-sheet surface. Similarly, in the second ( ) nucleation range a 
3β-sheet with one SH and one WH surface can elongate and the nucleus is a 2β-sheet 
with one β-strand attached with its WH side to the weak 2β-sheet surface. (b) As in 
(a), but in the first ( ) and second ( ) nucleation ranges the fibril nuclei are a 
1β and 2β-sheet (with two SH surfaces) with one β-strand attached to its WH and SH 
side, respectively. 
 
Due to their strong hydrogen bonds, the β-strands can arrange themselves laterally 
into β-sheets. The sheets consist of different number m of β-strands ( ,...3,2,1=m ) and 
are parallel to the fibril lengthening axis. Along its thickening axis the fibril is built up 
of iβ-sheets ( ,...3,2,1=i ) which are held together by e.g. relatively weak 
hydrophobicity-mediated bonds between the β-strands. Because the orientation of 
side-chains within a β-strand alternates, the hydrophobicity of the two β-sheet 
surfaces is generally different. In our model (49) we assume that for a 1β-sheet, i.e. a 
single β-sheet, the strongly hydrophobic (SH) surface is always on top (as indicated 
by the red surface/line in Figure 1) whereas the weakly hydrophobic (WH) surface is 
at the bottom (as indicated by the blue surface/line in Figure 1). In addition, a β-strand 
can only bind to a WH β-sheet surface with its WH side (blue binds to blue) and to an 
SH β-sheet surface with its SH side (red binds to red). Thus, the hydrophobicity of the 
surface of a nanofibril alternates with increasing number of β-sheets (red, blue, red, 
C
e
0 ≤C
1
≤C
e
C
1
>C
e
i = 0
i =1
i = 2
i =1 i = 2
! 5 
blue, etc.). Since the fibril width is fixed and equal to the β-strand length, the fibril 
can be considered as a 2D aggregate in the m,i plane, with building blocks (the β-
strands) arranged in a 2D lattice with simple rectangular symmetry.  
Essential parameters in our theory to describe the ontogenesis of the smallest 
nanosized amyloid fibrils are the dimensionless specific surface energies 
ψ = aσ / kT = E / 2kT  and ψw = ahσ w / kT = Ew / 2kT , ψs = ahσ s / kT = Es / 2kT of the 
fibril faces perpendicular to the lengthening m axis and the thickening i axis, 
respectively. The σ ’s are the dimensional specific surface energies of the fibril 
surfaces, the a’s are the areas of the β-strand faces (Figure 1), k is the Boltzmann 
constant, and T is the absolute temperature. The second equality in these equations 
results from using the approximate relations σ = E / 2a , σ
s
= E
s
/ 2a
h  and 
σ
w
= E
w
/ 2a
h
 between the σ ’s and the binding energies E’s between nearest 
neighbour β-strands (52).  
In order to model conformational polymorphism of β-strands within fibrils, it 
is necessary to introduce the binding energies ε  and ε
s
, ε
w
 between nearest-
neighbour amino acid due to hydrogen bonding, and to strong and weak hydrophobic 
bonding, respectively. Although our model can be applied to hetero polypeptides, for 
simplicity, in this work we only consider homo polypeptides for which the binding 
energies between amino acids in neighbouring β-strands are the same. Then the E’s 
can be written as E = nε , E
s
= n
s
ε
s
and E
w
= n
w
ε
w
, where n is the number of amino 
acids between two nearest-neighbour β-strands in a β-sheet that form hydrogen 
bonds, and ns, nw are the number of amino acids that form strong and weak 
hydrophobic bonds between nearest neighbour β-strands in successive β-sheets, 
respectively. The dimensionless specific surface energies ψs and ψw can then be 
written as  
ψ
s
= n
s
α
s
        (1) 
ψ
w
= n
w
α
w
        (2) 
where α
s
= ε
s
/ 2kT  and α
w
= ε
w
/ 2kT  are the dimensionless specific surface energies 
per amino acid due to strong and weak hydrophobic bonds, respectively.  
Importantly, the dimensionless specific surface energy ψ  can contain 
contributions from both nearest-neighbor hydrogen bonding and hydrophobicity-
mediated bonds and is given by  
ψ = nα + c
s
n
s
α
s
+ c
w
n
w
α
w       
(3) 
where α = ε / 2kT  is the dimensionless specific surface energies per amino acid due to 
hydrogen bonds, and cs, cw are parameters determining the contributions of  the strong 
and weak hydrophobicity-mediated bonds to ψ . For our illustrations we set
 
, which means that the contribution of the strength of the hydrophobicity 
mediated bonds to  is taken to be the average of the weak and strong hydrophobic 
surfaces.  
To calculate ψs, ψw and  for hetero polypeptides, the binding energies 
between amino acids pairs needs to be know, so that the dimensionless specific 
surface energies can be calculated by summation over amino acids pairs in 
neighbouring β-strands (53). 
 
Phase diagram  
c
s
= c
w
= 0.5
ψ
ψ
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A prerequisite for the application of nucleation theory to the formation of new phases 
is the understanding of the thermodynamic phase diagram. Experiments with different 
fibril polymorphs of Aβ40 show that their solubility differs (13, 54). Both theoretical 
considerations (30, 49, 51) and a computer-simulated peptide solubility diagram (55, 
56) reveal that for the irreversible elongation of differently thick amyloid fibrils 
thermodynamics requires different ranges of the concentration C1 of monomeric β-
strands (peptides or protein segments) in the solution. Figure 1 illustrates 
schematically these ranges at a fixed absolute temperature T at which the β-strands are 
in practically fully extended conformation. These ranges are limited by the 
equilibrium concentration (or solubility) Ce of the bulk fibrillar phase and the 
equilibrium concentrations (or solubilities) C
1β , C2β ,w , C2β ,s , C3β , etc. of the fibrils 
constituted of one β-sheet, two equally long β-sheets with two WH or two SH 
surfaces, three equally long β-sheets, etc., respectively. The solubilities are merely the 
C1 values at which the respective iβ-sheets, i.e. fibrils built up of i β-sheets, neither 
lengthen nor dissolve. The iβ-sheets with an odd number i of layers have always one 
WH and one SH surface and their solubility βiC  is related to Ce by the expression (49) 
( i =1,3, 5,... ) 
C
iβ =Ce exp (ψw +ψs ) / i[ ]       (4)  
The existence of two solubility values for iβ-sheets with an even number i of layers is 
due to the fact that they can have either two WH or two SH surfaces, respectively, and 
their solubilities C
iβ ,w  and Ciβ ,s  are related to Ce and by the expressions (49) (
i = 2, 4, 6,... ) 
C
iβ ,w =Ce exp(2ψw / i)        (5) 
C
iβ ,s =Ce exp(2ψs / i)        (6) 
In this work, we mostly consider the symmetric case when the hydrophobicity of both 
β-strand surfaces is the same, i.e. ψ
w
=ψ
s
≡ψ
h
, then the three equations above 
simplify to one (51) ( i =1,  2, 3, …) 
C
iβ =Ciβ ,w =Ciβ ,s =Ce exp(2ψh / i)      (7) 
As indicated in Figure 1, the β11 CC >  range (range 0=i  in the figure) corresponds to 
metanucleation, a process of fibril formation without energy barrier, because then 
each protein monomer (i.e. single β-strand) in the solution acts as fibril nucleus as 
attachment of another monomer to it allows irreversible elongation. When C
1
>C
2β ,w , 
2β-sheets with two weak hydrophobic surfaces can lengthen irreversibly. Importantly, 
in the C
2β ,w <C1 <C1β  range (range 1=i  in Figure 1) the 1β-sheets tend to dissolve 
and their appearance is due to fluctuations. In this range the fibril nucleus is a 1β-
sheet plus one β-strand attached with its SH side to the SH 1β-sheet side so that a 
fibril prenucleus is any of the randomly formed, differently long 1β-sheets in the 
solution. When C
1
>C
2β ,s , also the 2β-sheets with two strong hydrophobic surfaces 
can lengthen irreversibly, and in the C
2β ,s <C1 <C1β  range (range 1=i  in Figure 1) 
the corresponding fibril nucleus is a 1β-sheet plus one β-strand attached with its WH 
side to the WH 1β-sheet side (see Figure 1). The situation is analogous with the 3β-
sheets when β31 CC > , because then these sheets can elongate irreversibly, and in the 
C
3β <C1 <C2βw  or C3β <C1 <C2βs  ranges (range 2=i  in Figure 1), the fibril nucleus 
is a 2β-sheet with one β-strand attached sidewise. 
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The general rules are, therefore, that in the ith supersaturation range, defined 
by (49) (i =1,  3, 5, …) 
C
e
exp 2ψ
w
/ (i+1)[ ] <C1 <Ce exp (ψw +ψs ) / i[ ]    (8) 
C
e
exp 2ψ
s
/ (i+1)[ ] <C1 <Ce exp (ψw +ψs ) / i[ ]    (9) 
the fibril nuclei are composed of an odd number i of β-sheets plus one β-strand 
attached to the SH or WH side, respectively (Figure 1). In these ranges, all different 
length iβ-sheets are fibril prenuclei, and these sheets plus one iβ-strand attached to the 
WH or SH surface, are the fibril nuclei for the (i+1)β-sheet-thick fibrils with either 
two WH or SH sides that can lengthen irreversibly. Similarly, in the ith 
supersaturation range, defined by (i = 2,  4, 6, …) 
C
e
exp (ψ
w
+ψ
s
) / (i+1)[ ] <C1 <Ce exp(2ψw / i)    (10) 
 C
e
exp (ψ
w
+ψ
s
) / (i+1)[ ] <C1 <Ce exp(2ψs / i)    (11) 
the fibril nuclei are composed of an even number i of β-sheets plus one β-strand 
attached to the SH or WH side, respectively (Figure 1). For the symmetric case (then 
ψ
s
=ψ
w
≡ψ
h
), the four equations above simplify to one general rule that in the ranges 
(51) (i = 0,  1, 2, 3, …)  
C
e
exp 2ψ
h
/ (i+1)[ ] <C1 <Ce exp(2ψh / i)     (12) 
all differently long iβ-sheets are fibril prenuclei, and these sheets plus one β-strand 
attached to one of their two sides are the nuclei of the ( 1+i )β-sheet-thick fibrils that 
can lengthen irreversibly. 
 
Nucleation rate  
Which fibrils form in a protein solution, and how fast, is determined by the nucleation 
rate J (m
-3
 s
-1
). Experiments on protein aggregation are often performed at fixed 
temperature T, and based on the phase diagram discussed above we can write down 
expressions for J in the nucleation and metanucleation ranges. The concentration 
dependence of the nucleation rate in the metanucleation range (range 0=i  in Figure 
1) in which each monomer in the solution acts as fibril nucleus is given by (49) (
C
1
>C
1β ) 
J = A
1
C
1
2
(1− A
2
C
1
−1
)         (13) 
where A
1
= 2k
e
/C
e
, A2 =Ce exp(ψw +ψs ) , ke is the attachment frequency of 
monomers to one of the two hydrogen-bond sides of a given monomer at equilibrium, 
Ce is the fibril solubility, and the threshold concentration C1β , given by  
C1β =Ce exp(ψs +ψw )        (14)  
is obtained from  eq (4) with . For the symmetric case (then ψ
s
=ψ
w
≡ψ
h
), the 
constants simplify to (30): , A2 =Ce exp(2ψh )  
and C1β =Ce exp(2ψh ) . 
The formula for J in the ith nucleation range when the fibril nuclei are 
composed of an odd number (i =1,  3, 5, …) of β-sheets plus one β-strand 
(corresponding to supersaturation ranges i =1,  3, 5, …) is given by (49)  
J = A
1
C
1
i+2 1− A2C1
−1
1− A
3
C
1
i( )
2        (15) 
with A1 = (2ke /Ce
i+1
)exp(−2ψi−ψ
w
+ψ
s
) and A2 =Ce exp 2ψw / (i+1)[ ]  (for 
C
e
exp 2ψ
w
/ (i+1)[ ] <C1 <Ce exp (ψw +ψs ) / i[ ] ) or 
1=i
A
1
= 2k
e
/C
e
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A1 = (2ke /Ce
i+1
)exp(−2ψi−ψ
s
+ψ
w
) and A2 =Ce exp 2ψs / (i+1)[ ]  (for 
C
e
exp 2ψ
s
/ (i+1)[ ] <C1 <Ce exp (ψw +ψs ) / i[ ]  when the β-strand is on the nucleus SH 
or WH side, respectively. The constant A3 is given by A3 =Ce
−i
exp −(ψ
w
+ψ
s
)[ ]
 
in 
both cases.  
When the fibril nuclei are composed of an even number  of β-
sheets plus one β-strand (supersaturation ranges i = 2 , 4, 6, …), the fibril nucleation 
rate is given again by eq (15), but with A1 = (4ke /Ce
i+1
)exp(−2ψi) and 
A2 =Ce exp (ψw +ψs ) / (i+1)[ ] . As to the constant A3, it is given by 
A3 =Ce
−i
exp(−2ψ
w
)  (for C
e
exp (ψ
w
+ψ
s
) / (i+1)[ ] <C1 <Ce exp(2ψw / i) ) when the β-
strand is on one of the prenucleus two WH sides,
 
or by A3 =Ce
−i
exp(−2ψ
s
)  (for 
C
e
exp (ψ
w
+ψ
s
) / (i+1)[ ] <C1 <Ce exp(2ψs / i) ) when the β-strand is on one of the 
nucleus two SH sides. For the symmetric case, the fibril nucleation rate is given again 
by eq (15), but with A1 = (4ke /Ce
i+1
)exp(−2ψi) , A2 =Ce exp 2ψh / (i+1)[ ] , and
A3 =Ce
−i
exp(−2ψ
h
)
 
in the supersaturation ranges specified by eq (12).  
 
Fibril solubility  
Different fibril polymorphs will have different solubilities (13, 54). As the effect of 
changing molecular interactions between β-strand on C
e
 is not always known 
experimentally, we estimate it theoretically by making use of the van’t Hoff equation 
and the Haas-Drenth lattice model (57) for protein crystals. The integrated van’t Hoff 
equation is given by C
e
=C
r
exp(−λ) where C
r  
is a practically temperature 
independent reference concentration and λ = L / kT is the dimensionless latent heat of 
peptide aggregation into β-sheets. Here L is the latent heat of peptide aggregation into 
such aggregates. In the Haas-Drenth lattice model (57) for protein crystals λ is half 
the dimensionless binding energy of peptides in the aggregates, which is equivalent to 
the dimensionless broken bond energy λ = 2ψ +ψ
s
+ψ
w
 at the periphery of a fibril in 
the m,i plane. The fibril solubility is then given by  
C
e
=C
r
exp −2ψ −ψ
s
−ψ
w( )       (16) 
and simplifies to C
e
=C
r
exp −2(ψ +ψ
h
)[ ]
 
in the symmetric case.  
 
RESULTS 
 
The recipe to apply our newly developed non-standard nucleation theory to predict 
the  dependence for different fibril polymorphs is as follows: (1) Calculation of 
the dimensionless specific surface energies ψs, ψw and  for different fibril 
polymorphs from eqs 1 to 3. This requires the knowledge of the conformation of the 
β-strands in the fibril as they define the number n of bonds between amino acids, and 
the associated binding energies between them. (2) Calculation of the fibril solubility 
 for different fibril polymorphs from eq 16. This requires the knowledge of  for 
one fibril polymorph that serves as a reference structure. (3) Calculation of the  
dependence from eqs 13 to 15, which requires knowledge of the elongation rate k
e
. 
We apply this recipe to the fibril polymorphs illustrated in Figure 2. As already 
... ,6 ,4 ,2=i
J(C
1
)
ψ
C
e
C
e
J(C
1
)
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mentioned in the introduction, the emphasis of this work is to provide conceptual 
insight into factors can tip the nucleation process in favour of one or another fibril 
polymorph. For this reason we will apply our theoretical framework to a model 
peptide rather than to a specific protein. 
    
 
 
Figure 2. Illustration of fibril polymorphs considered in this work. Conformational 
polymorphism where the fibril polymorphs are composed of extended β-strand of 
different lengths (9 or 11 amino acids) (a), and β-strands in an extended or hairpin 
conformation (b). Stacking polymorphism where the fibril polymorphs are composed 
of extended β-strands that stack either parallel or anti-parallel in β-sheets (c), and β-
sheets that stack either by binding with their two WH or two SW surfaces (d). The red 
and blue surfaces indicate the SH and WH β-strand sides, respectively. The light grey 
and light orange surfaces indicate the strong and weak hydrogen bonding β-strand 
sides, respectively. 
  
Conformational polymorphism  
Perhaps the simplest example of conformational polymorphism is where the number 
of amino acids of the β-strands within a fibril differs. The β-strand length is relevant 
because it has been associated with polyglutamine disorders (50). Polyglutamine 
disorders are a class of nine neurodegenerative disorders including Huntington’s 
disease associated with the aggregation of polyglutamine repeats. The hallmark 
feature of these diseases is that the onset of the disease correlates with the length of 
the polyglutamine repeats. The aggregation and pathologies are typically observed 
above a threshold of 35-40 repeats, and the longer the repeat the sooner the symptoms 
appear (50, 58). In order to illustrate the effect of the β-strand length on the J(C1)  
dependence we consider β-strands composed of 9, 10 and 11 amino acids (Figure 2a) 
that assemble in their fully extended conformation in a nanosized amyloid fibril. Step 
(1) of the recipe is to determine the dimensionless specific surface energies. As the 
structure of the β-strands in the fibril is fully extended, the number n of amino acids 
that form hydrogen bonds between two-nearest neighbour β-strands in a β-sheet and 
the numbers nw, ns of amino acids that form hydrophobic bonds between two-nearest 
neighbour β-strands are the same and given by n = n
s
= n
w
= 9 , 10 and 11 for β-
strands of length 9, 10, and 11, respectively. Assuming that the dimensionless specific 
surface energy per amino acid due to hydrogen-bonding is 1 (corresponding to 
ε = 2 kT, a value in the range of hydrogen bonding energies measured experimentally 
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(59)), that the ones due to strong and weak hydrophobic bonds are 0.1 
(corresponding to ε
s
= ε
w
= 0.2 kT, a value typically used in protein simulations (60)), 
and that the parameter , the values for the dimensionless specific surface 
energies are obtained from eqs 1 to 3 and given by ψ = 9.9 , ψ
s
=ψ
w
=ψ
h
= 0.9  for β-
strands of length 9, ψ =11 , ψ
s
=ψ
w
=ψ
h
=1  for β-strands of length 10, and by 
ψ =12.1 , ψ
s
=ψ
w
=ψ
h
=1.1  for β-strands of length 11. These ψ  values are in the 
range of values estimated for short fibrils (31, 56). Step (2) of the recipe is to 
calculate of the fibril solubility  for different fibril polymorphs. Assuming that the 
fibril solubility for fibrils composed of β-strands with 10 amino acids is
 
 m
-3
 (= 10 µM) (e.g. ref (61)), we calculate from eq 16 that 
C
r
=1.6×10
32  m
-3
. Importantly, as the binding energies of β-strands with different 
lengths within the fibrils are different, their fibril solubilities are different (see 
methods). Assuming that C
r
=1.6×10
32 m
-3 
is independent of the length, and 
substituting C
r
 and the ψ , ψ
h
 values above in eq 16, the solubilities for fibrils 
composed of peptides composed of 9 and 11 amino acids are C
e
= 6.62×10
22  m
-3
 (= 
110 µM) and C
e
= 5.41×10
21
 
m
-3
 (= 0.9 µM), respectively. Figure 3a illustrates the so 
obtained (exponential) decrease of C
e  
with increasing length (eq 16).  
 
 
Figure 3. Solubility Ce (diamonds) and threshold concentration  (crosses) of 
fibrils composed of (a) extended β-strands of length 9, 10 and 11 amino acids. The 
corresponding values for the dimensionless surface energies are 0.9, 1, 1.1 and 
9.9, 11, 12.1 for length 9, 10, and 11, respectively. (b) extended β-strands and β-
strands in a hairpin conformation. The corresponding surface energies are  11 (for 
both) and 1 (extended) or 0.5 (hairpin). (c) extended β-strands arranged parallel 
and anti-parallel. The corresponding surface energies are 1 (for both) and 10 
(anti-parallel) or 11 (parallel). (d) extended β-strands with asymmetric hydrophobic 
surfaces between β-sheets. The corresponding values for the dimensionless surface 
energies are 1 (for all) and 11, 10.75 and 1, 0.5 for the symmetric and 
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the asymmetric hydrophobic surfaces, respectively. In all panels the solid red and 
black lines are obtained from equations (14) and (16), respectively.  
 
Step (3) of the recipe is to calculate the  dependence for the different fibril 
polymorphs. Using a typical value for the fibril elongation rate  s
-1
 (e.g. ref 
(28)), and assuming that it is independent of the length, allows us to calculate the 
 dependence from eqs 13 to 15 with the A’s for the symmetric case (because 
ψ
s
=ψ
w
=ψ
h
). As can be seen in Figure 4a, the characteristic feature of the  
dependence is the sharp rise at the transition concentrations C
iβ  over a very narrow 
concentration range; 7 orders of magnitude at the nucleation/metanucleation border 
 
 and even more at C
2β . As mentioned in the introduction, such a sharp rise in the 
nucleation rate is a peculiar kind of nucleation and does not comply with standard 
nucleation theory (30). The importance of 
 
comes from the fact that it appears as a 
threshold concentration below which fibril formation becomes biologically irrelevant, 
because only one fibril can be nucleated within a day in volumes of about 1 µm3 or 
smaller, comparable to that of a cell.  
 
 
 
Figure 4. Concentration dependence of the nucleation rate J for fibrils composed of 
(a) extended β-strands of length 9, 10 and 11 amino acids (as indicated). (b) extended 
β-strands and β-strands in a hairpin conformation (as indicated). (c) extended β-
strands arranged parallel and anti-parallel (as indicated). (d) extended β-strands with 
symmetric and asymmetric hydrophobic surfaces between β-sheets as indicated. In 
the asymmetric case the label WH and SH indicate the nucleation rate where the fibril 
nuclei is a 1β-sheet plus one β-strand attached to the SH and WH side of the sheet, 
respectively. The corresponding values for the dimensionless surface energies are as 
in Figure 3. In all cases, the black and red lines indicate the rate in the metanucleation 
and nucleation ranges, respectively.  
 
Figure 4a also shows that the main effect of increasing the β-strand length on the 
J(C
1
)  dependence is to shift C
1β  to lower concentrations and to promote protein 
fibrillation, because metanucleation commences at lower C
1
 values. Using the Ce 
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values calculated above in eq 14, the threshold concentrations for fibrils with 9, 10 
and 11 amino acids are C
1β = 4.0×10
23  m
-3
 (= 665.5 µM),  m-3 (= 73.8 
µM), and C
1β = 4.9×10
21  m
-3
 (= 8.1 µM), respectively (Figure 3a). The dependence 
of C
1β  on Ce  
(eq 14), however, highlights that C
e
 is the determining factor in 
amyloid fibril nucleation and is the main reason why fibrils composed of longer β-
strands nucleate faster. Even though we have considered here only a short model 
peptide, the prediction that the nucleation rate increases with increasing β-strand 
length is compatible with the experimental observation that the onset of the disease 
correlates with the length of the polyglutamine repeats (50). 
Another example of conformational polymorphism in amyloid fibrils has been 
reported for the amyloid-β peptide where the Aβ40 peptide is in an extended and a 
hairpin conformation (10, 12). In order to investigate how such a change in the 
conformation affects the J(C1)  dependence, we consider fibrils composed of β-
strands with 10 amino acids in an extended conformation (as above) and a hairpin 
conformation (Figure 2b). The main difference for fibrils composed of β-strands in a 
hairpin conformation is that only half of the amino acids of the β-strand contribute to 
the hydrophobicity-mediated bonds between successive β-sheets and therefore 
. All other parameters are the same (i.e. , , and 
). As in the previous example, the values for the dimensionless surface 
energies for fibrils composed of β-strands in a hairpin conformation are obtained from 
eqs 1 to 3 and are given by 11,   (step (1) of recipe). The value 
11 is the same for both fibril polymorphs, as the number of hydrogen and 
hydrophobic bonds in direction of the fibril lengthening axis is the same. Using again 
C
r
=1.6×10
32  m
-3
 with ψ =11 , ψ
h
= 0.5  in eq 16, shows that the conformational 
change shifts  m
-3
 (= 27.1 µM) to slightly higher concentrations, see 
Figure 3b (step (2) of recipe). As in the previous example, we calculate the J(C1)  
dependence from eqs 13 to 15 with  s
-1
 and the A’s for the symmetric case 
(step (3) of recipe). Figure 3b shows that the main effect of this conformational 
change is a small decrease of J(C1)  mainly because the threshold concentration 
C
1β = 4.4×10
22  m
-3 
(= 73.8 µM) is unchanged. This can be shown by substitution of 
eq 16 into eq 14 which eliminates 
 
in the exponents of , so that it only 
depends on . Thus, the shift of  to slightly higher concentrations compensates 
the corresponding shift of  to lower ones. The prediction that the nucleation rates 
of fibrils composed of peptides in an extended β-strand and hairpin conformation 
differ only slightly might explain why both fibril structures have been observed 
experimentally (10, 12).  
 
Packing polymorphism  
We first consider packing polymorphism where β-strands within β-sheets arrange 
parallel or anti-parallel (Figure 2c), as it has been observed in fibrils of short peptides 
and natural proteins (7, 22). As before, the fibril building block is the extended β-
strands composed of 10 amino acids. To distinguish between parallel and anti-parallel 
stacking, we assume that the hydrogen bonding energy between β-strands in a β-sheet 
when stacked in anti-parallel arrangement is weaker compared to when stacked 
C
1β = 4.4×10
22
n
s
= n
w
= n / 2 = 5 α =1 α
w
=α
s
= 0.1
c
w
= c
s
= 0.5
ψ = ψs =ψw =ψh = 0.5
ψ =
C
e
=1.63×10
22
k
e
=10
−4
ψ
s
,ψ
w C1β
ψ Ce
C
1β
! 13 
parallel. Thus, for anti-parallel stacking we set the specific surface energy per amino 
acid due to hydrogen bonding to α = 0.9  which is smaller compared to α =1  for 
parallel arrangement. All other values for the model parameter are unchanged (i.e. 
 and n
s
= n
w
= n =10 ). The corresponding value for the dimensionless 
surface energy due to hydrogen bonding for anti-parallel stacking is ψ = 10 
(calculated as before), whereas the values for the surface energy due to 
hydrophobicity-mediated bonds are ψ
s
=ψ
w
=ψ
h
= 1 as before (step (1) of recipe). 
The fibril solubility C
e
= 4.4×10
22  m
-3
 (= 74 µM) is obtained from eq 16 with 
 m
-3
 (step (2) of recipe), which shows that a change in the arrangement 
of the β-strand in a β-sheet from parallel to anti-parallel shifts C
e
 to much higher 
concentrations (Figure 3c). Assuming again that k
e
=10
−4  s
-1
 is independent of the 
stacking, the J(C1)  dependence is calculated from eqs 13 to 15 with the A’s for the 
symmetric case (step (3) of recipe), illustrating that a change in the arrangement of the 
β-strands in a β-sheet from parallel to antiparallel shifts C
1β  to higher concentration 
and that it hampers protein fibrillation because metanucleation commences at higher 
C
1
 values (Figure 4c). Using the Ce value calculated above in eq 14, the threshold 
concentration is C
1β = 3.3×10
23
 
m
-3
 (= 545 µM) (see Figure 3c). It is worth noting 
that a mixture of parallel and anti-parallel fibrils in the protein solution can only be 
observed at concentrations in the metanucleation range of both fibrils, i.e. when 
C
1
>C
1β = 545  µM, and provided that the magnitude of the metanucleation rates are 
comparable and sufficiently high (see Figure 4c). Importantly, as a priory it is not 
known whether anti-parallel stacking decreases the specific surface energy per amino 
acid due to hydrogen bonding, we could also have assumed that this stacking 
increases it, in which case anti-parallel fibrils would nucleate faster. The general rule 
is, however, that increasing the specific surface energy per amino acid due to 
hydrogen bonding promotes protein fibrillation, and the strong effect on the  
dependence might explain that a single point mutation can switch the fibril 
morphology from predominately parallel to predominately antiparallel (22).  
Another example of packing polymorphism is when β-sheets stack differently 
as observed in short peptides (7). Along its thickening axis the fibril is built up of β-
sheets which are held together by e.g. relatively weak hydrophobicity-mediated bonds 
between the β-strands. Because the orientation of side-chains within a β-strand 
alternates, the hydrophobicity of the two β-sheet surfaces is generally different. This 
asymmetry leads to fibrils that can either have two strong, two weak or one strong and 
one weak hydrophobic surface (Figure 2d), but which ones form? As in our previous 
work (49), to model the effect of asymmetry we decrease the weak specific surface 
tension per amino acid  due to hydrophobic bonding between β-strands in consecutive 
β-sheets to  while α
s
= 0.1  is kept constant. The values of all other 
parameter are the same as for the extended β-strand with symmetric hydrophobic 
surfaces  (i.e c
s
= c
w
= 0.5 , n
s
= n
w
= n =10 ). The corresponding values for the 
dimensionless surface energies are obtained from equations 1 to 3 and are given by 
ψ
s
=1, ψ
w
=0.5, ψ =  10.75 (step (1) of recipe), and the corresponding asymmetry 
ratio is ψ
w
/ψ
s
= 0.5 . The fibril solubility is again obtained from eq 16 and is given by 
C
e
= 7.3×10
22
 
m
-3
 (= 27 µM) (step (2) of recipe). Thus, increasing the asymmetry (by 
c
w
= c
s
= 0.5
C
r
=1.6×10
32
J(C
1
)
α
w
= 0.05
! 14 
decreasing the asymmetry ratio) shifts C
e
 to higher concentrations (Figure 3d). We 
calculate the  dependence from eqs 13 and 15 with  s
-1
 and the A’s for 
the asymmetric case (step (3) of recipe). A characteristic feature in this case is, 
however, that in given concentration range there exist different fibril nuclei  (see 
Figure 1). In Figure 4d we show that in the first nucleation range (range  in 
Figure 1), the nucleation rate for fibrils where the fibril nucleus is a single β-sheet 
plus one β-strand attached to the SH side can be substantially higher than that where 
the β-strand is attached to the WH side. This implies that in the concentration range 
 there is a morphological selection as only fibrils with two WH 
surfaces can grow, whereas the ones with two SH cannot (see Figure 1). The values 
for C
2β ,w = 2.7×10
22  m
-3
 (= 45 mM) and C
2β ,s = 4.4×10
22  m
-3
 (= 74 mM) are 
obtained from eqs 5 and 6. In Figure 4d we also show the corresponding  
dependence for the symmetric case, which shows that the main effect of increasing 
the asymmetry (decreasing  at constant ) is to shift  to higher concentration 
and to hamper protein fibrillation, because metanucleation commences at higher  
values. Using the Ce values calculated above in eq 14, the threshold concentrations for 
fibrils with asymmetry ratios 0.5 is C
1β = 7.3×10
22
 
m
-3
 (= 121 mM). A solution 
mixture containing fibrils with two strong, two weak, and one strong and one weak 
hydrophobic surface can only be observed at concentrations in the metanucleation 
regime of all fibrils, i.e. when C
1
>C
1β =121 
mM provided the magnitude of the 
metanucleation rates are comparable and sufficiently high (see Figure 4d). Note that 
although the effect of asymmetry is due to changes in the hydrophobicity (as in the 
case of the conformational change from an extended β-strand to a hairpin), the shift of 
C
e
 to higher concentrations does not compensate the corresponding shift of  to 
lower ones. This is so, because a change in α
w
 also changes ψ  (see eq 3), which is 
not the case when the conformation changes from an extended β-strand to a hairpin. 
The effect of asymmetry on the  dependence provides new insight into how a 
change in the side-chain side-chain interactions between the β-strands can lead to a 
change in the stacking of β-sheets within fibrils (7). 
 
DISCUSSION 
 
Fibrils solubility and polymorphism 
The results obtained highlight the important role of the threshold concentration C
1β  
and the fibril solubility  in amyloid fibril nucleation, and they illustrate that C
e
 is 
the determining factor because C
1β  depends on Ce (eq 14). Describing the 
phenomenon of fibril polymorphism on the basis of fibril solubility  and the 
threshold concentration C
1β  provides an alternative view on this important problem, 
and it opens new ways to control the formation of particular fibril polymorphs 
experimentally by changing  and . Therefore we express both quantities in 
terms of the binding energies between neighbouring β-strands in the fibril. An 
approximate relation between  and the binding energies can be obtained by 
substitution of  eqs  1 to 3 into eq 16. This gives  
J(C
1
) k
e
=10
−4
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C
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/ 2+ n
w
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w
/ 2) / kT[ ]
  
(17)
 
where ε , ε
s
, and ε
w
 are the binding energies between nearest neighbour amino acids 
due to hydrogen bonding and to strong and weak hydrophobic bonds, respectively. 
The n’s are the corresponding number of these bonds, and cs, cw are parameters 
determining the contributions of hydrophobicity-mediated bonds. Similarly, the 
dependence of C
1β  on the binding energies is obtained by substitution of eqs 1, 2 and 
17 into eq 1 
 C1β =Cr exp −(nε + csnsεs + cwnwεw ) / kT[ ]     (18) 
These two relatively simple equations allow us to understand and rationalize the 
results obtained for the concentration dependence of the nucleation rate for different 
fibril polymorphs in terms of changes in the binding energies. First we consider the 
conformational polymorphism due to an increase of the β-strand length within fibrils. 
Figures 3a and 4a illustrate that increasing the β-strand length decreases C
e
 and 
promotes protein fibrillation because C
1β  is shifted to much lower C1  values. The 
reason for this is that increasing the β-strand length increases n, ns and nw, which 
decreases both C
e
 and C
1β (eqs 17 and 18). As ε is ten times larger than εs and εw, 
however, this decrease is dominated by the increase in the binding energy due to 
hydrogen bonds. Second, we consider the packing polymorphism due to parallel or 
anti-parallel stacking of β-strands in a β-sheet. Figures 3c and 4c illustrate that a 
change in the stacking of the β-strands in a β-sheet from parallel to antiparallel 
increases both C
e
, C
1β  and thereby hampers protein fibrillation. This decrease is 
solely due to the decrease in the hydrogen bonding energy, as a change in the stacking 
arrangement only lowers ε, whereas εs and εw are unchanged (see eqs 17 and 18). 
Third, we consider the conformational polymorphism due to a change in the 
conformation of the β-strand from extended to hairpin. Figures 3b and 4b illustrate 
that this conformational change only increases C
e
, whereas C
1β  
is unchanged and 
consequently protein fibrillation is only slightly hampered. As this conformational 
change only decreases the numbers ns, nw of hydrophobic contacts between β-strands 
in consecutive β-sheets (and not n), this effect is entirely due a change in the 
hydrophobic binding energy (see eqs 17 and 18). Forth, we consider the packing 
polymorphism due to the asymmetry between the weak and strong hydrophobic β-
strand surfaces that can lead to different packing of β-sheets within fibrils. Figures 3d 
and 4d show that increasing the asymmetry increases both C
e
 and C
1β  
thereby 
hampering protein fibrillation. This effect is also entirely due to an decrease in the 
hydrophobic binding energy between β-strands as with increasing asymmetry only εw 
is lowered, whereas ε and εs are unchanged (see eqs 17 and 18). The morphological 
selection between fibrils with two WH and SH β-sheet surfaces occurs thanks to the 
inequality C
2β ,w <C2β ,s , and by substitution of eqs 1, 2 and 17 into eqs 5 and 6 it can 
be shown that this inequality is due to the fact that εw < εs.  
 
General rule 
The considerations of these four examples reveal a general rule underlying fibril 
polymorphism, namely that changes in the conformation of the fibril building blocks 
or their packing that increase their binding energy within fibrils (due to both hydrogen 
and hydrophobic bonds) lowers the fibril solubility C
e
 and hence the threshold 
! 16 
concentration  which in turn promotes protein fibrillation. Or in other words, the 
nucleation rate of the fibril polymorphs composed of fibril building blocks with 
higher binding energy is higher. Although this rule seems intuitive, here we show that 
it naturally emerges by treating the nucleation of amyloid fibrils into polymorphic 
structures within our newly developed non-standard nucleation. The power of the 
presented theoretical framework is that it provides a tool to both qualitatively and 
quantitatively predict which polymorph forms based on the fundamental interactions 
between the fibril building blocks. 
 
Limitations 
Finally, we emphasize that the results obtained above apply to one-step fibril 
nucleation, i.e when the monomeric β-strands polymerize directly into fibrils, and that 
the analysis treats homogeneous nucleation of amyloid fibrils occurring when 
nucleation-active foreign particles or substrates are absent from the solution. Two-
step nucleation of polymorphic fibrils, and fibril polymorphism that occurs during 
fibril growth, or is determined by fibril growth, are not considered. Importantly, the 
application of the general expressions for the fibril nucleation rate J as an explicit 
function of the concentration to different fibril polymorphs requires that the reference 
concentration Cr and the attachment frequency ke of monomers to one of the two fibril 
ends at equilibrium are constant. Furthermore, the relation between the fibril 
solubility and the binding energies is approximate and pertains to sufficiently low 
temperatures. It should also be mentioned that the entropy loss when a β-strand is 
attached to the fibril is taken into account in our newly developed non-standard 
nucleation model (30, 49). This is so, because in contrast to classical nucleation 
theory, in the derivation of the analytical expression for the nucleation rate, the length 
distribution of fibril nuclei in the solution is considered (see Figure 3 of Ref. (30)). 
The remarkably good description of simulation data for the nucleation rate by our so-
derived expression (see Figure 5 of Ref. (30)) indicates that entropy effects is indeed 
well accounted for. Such effects, however, due to vibrations of the β-strand within 
fibrils are not explicitly considered, but ideas of how to do that can be found in Ref. 
(62) and they could be the basis of an important extension of our model. The entropic 
effects, however, are automatically accounted for when experimental data for Ce and 
ψ, ψh are used.   
 
CONCLUSIONS 
 
Summing up, we conclude that the nucleation of polymorphic amyloid fibrils can be 
treated within our newly developed non-standard nucleation theory. This treatment 
allows the prediction of the  dependence for different fibril polymorphs, which 
highlights the important role of the threshold monomer concentration  and the 
protein solubility C
e
. The focus of experimental studies on amyloids is often on their 
structure, assembly mechanism and their interactions with the biological environment. 
Not so many experiments focus on determining the fibril solubility and how it 
changes with the fibril structure and amino acid sequence. Describing the 
phenomenon of fibril polymorphism on the basis of fibril solubility and the 
threshold concentration  opens up new ways to design experimental strategies to 
stimulate or prevent the formation of particular fibril polymorphs, and for this our 
C
1β
J(C
1
)
C
1β
C
e
C
1β
! 17 
approximate relations between C
e
,  and the binding energies between 
neighbouring β-strands in the fibril (eqs 17 and 18) might prove a valuable tool.  
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